239 related articles for article (PubMed ID: 27186712)
1. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
Cicero TJ; Ellis MS; Kasper ZA
Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
[TBL] [Abstract][Full Text] [Related]
2. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
3. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
4. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
5. A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population.
Jewell J; Black J; Ellis M; Olsen H; Iwanicki J; Dart R
Clin Drug Investig; 2023 Mar; 43(3):197-203. PubMed ID: 36859697
[TBL] [Abstract][Full Text] [Related]
6. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
Vosburg SK; Haynes C; Besharat A; Green JL
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
[TBL] [Abstract][Full Text] [Related]
7. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
Rauck RL
Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
[TBL] [Abstract][Full Text] [Related]
8. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
[TBL] [Abstract][Full Text] [Related]
9. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodone.
Nalamachu S; Kopecky EA; Taylor R; Vaughn B; O'Connor M
Curr Med Res Opin; 2016 Jul; 32(7):1311-7. PubMed ID: 27025986
[TBL] [Abstract][Full Text] [Related]
11. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
12. Development and impact of prescription opioid abuse deterrent formulation technologies.
Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
[TBL] [Abstract][Full Text] [Related]
13. Abuse-deterrent opioids: an update on current approaches and considerations.
Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
[TBL] [Abstract][Full Text] [Related]
14. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
[TBL] [Abstract][Full Text] [Related]
16. Acute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging.
Bonnecaze AK; Wilson MW; Dharod A; Fletcher A; Miller PJ
Nephrology (Carlton); 2018 Oct; 23(10):921-926. PubMed ID: 28802086
[TBL] [Abstract][Full Text] [Related]
17. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
18. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
19. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone.
Schoedel KA; McMorn S; Chakraborty B; Zerbe K; Sellers EM
Pain Physician; 2010; 13(6):561-73. PubMed ID: 21102969
[TBL] [Abstract][Full Text] [Related]
20. Emerging Trends in Abuse-Deterrent Formulations: Technological Insights and Regulatory Considerations.
Rana D; Salave S; Benival D
Curr Drug Deliv; 2022; 19(8):846-859. PubMed ID: 34879799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]